Extreme Prematurity
0
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Providence TherapeuticsAB - Calgary
1 programEvaluating Decisional Regret Among MothersN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
ChiesiLISA
Providence TherapeuticsEvaluating Decisional Regret Among Mothers
Clinical Trials (2)
Total enrollment: 271 patients across 2 trials
LISA in the Delivery Room for Extremely Preterm Infants
Start: Jun 2021Est. completion: Apr 202560 patients
N/ACompleted
Evaluating Decisional Regret Among Mothers
Start: Mar 2020Est. completion: Jun 2021211 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.